Clinical Trial Update: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating belumosudil combined with rituximab as primary treatment for chronic graft-versus-host disease is currently in the recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Belumosudil (belumosudil)
• Rituximab (rituximab)

Snippet

Sponsor: Northside Hospital, Inc. | Conditions: Chronic Graft Versus Host Disease | Phase 2 | Status: RECRUITING